Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

Importance Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet
therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited …

Background Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major
trials focusing on the clinical benefits of catheter-directed treatment, heparin …

Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …

Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention
has developed into its own subspecialty of interventional cardiology. Dedicated terminology …

Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …

Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …

Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

Background Current guidelines recommend potent platelet inhibition with ticagrelor or
prasugrel in patients after an acute coronary syndrome. However, data about optimal …

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent
thromboembolic events without substantially increasing bleeding. We explored the …